Citations

Clear

4 citation(s) found for "Laslavic, Angela".

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Chen, Denise, Corona, Rosario I. , Fu, Zhuxuan , Murali, Rajmohan , Köbel, Martin , Tazi, Yanis , Cunningham, Julie M. , Wiley, Brian , Armasu, Sebastian M. , Lester, Jenny , Laslavic, Angela , Kennedy, Catherine J. , Piskorz, Anna , Sekowska, Magdalena , Brand, Alison H. , Chiew, Yoke-Eng , Drapkin, Ronny , Gourley, Charlie , Brenton, James D. , Weigelt, Britta , Anglesio, Michael S. , Huntsman, David G. , Gayther, Simon A. , Lawrenson, Kate , Goode, Ellen L. , Papaemmanuil, Elli , Bolton, Kelly L , Corona de la Fuente, Rosario , Fu, Zhuxuan , Murali, Rajmohan , Köbel, Martin , Tazi, Yanis , Cunningham, Julie M , Moukarzel, Lea A , Winham, Stacey J , Elishaev, Esther , Kennedy, Catherine J , Sekowska, Magdalena , Brand, Alison H , Chiew, Yoke-Eng , Pharoah, Paul D P , Elias, Kevin M , Drapkin, Ronny , Churchman, Michael , Gourley, Charlie , Fazio, Anna de , Karlan, Beth Y , Brenton, James D , Weigelt, Britta , Anglesio, Michael S , Modugno, Francesmary , Lawrenson, Kate , Goode, Ellen L , Bolton, Kelly L. , Chan, Irenaeus C.C. , Moukarzel, Lea A. , Winham, Stacey J. , Elishaev, Esther , Pharoah, Paul D.P. , Elias, Kevin M. , DeFazio, Anna , Karlan, Beth Y. , Konner, Jason A , Modugno, Francesmary

Mayo Clinic

Clinical Cancer Research | July 11, 2022 | Volume: 28 | Issue: 22 | Pages: 4947-4956

10.1158/1078-0432.ccr-21-3817 | PMID 35816189 Get It

Abstract Purpose: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. Experimental Design: We profiled 421 primary CCOCs that passed quality control using a targeted deep sequencing panel of 163 putative CCOC driver genes and whole transcriptome sequencing of 211 of these tumors. Molecularly defined subgroups were identified and tested for association with clinical characteristics and overall survival. Results: We detected a putative somatic driver mutation in at least one candidate gene in 95% (401/421) of CCOC tumors including ARID1A (in 49% of tumors), PIK3CA (49%), TERT (20%), and TP53 (16%). Clustering of cancer driver mutations and RNA expression converged upon two distinct subclasses of CCOC. The first was dominated by ARID1A-mutated tumors with enriched expression of canonical CCOC genes and markers of platinum resistance; the second was largely comprised of tumors with TP53 mutations and enriched for the expression of genes involved in extracellular matrix organization and mesenchymal differentiation. Compared with the ARID1A-mutated group, women with TP53-mutated tumors were more likely to have advanced-stage disease, no antecedent history of endometriosis, and poorer survival, driven by their advanced stage at presentation. In women with ARID1A-mutated tumors, there was a trend toward a lower rate of response to first-line platinum-based therapy. Conclusions: Our study suggests that CCOC consists of two distinct molecular subclasses with distinct clinical presentation and outcomes, with potential relevance to both traditional and experimental therapy responsiveness. See related commentary by Lheureux, p. 4838
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze, Karolin , Nazeran, Tayyebeh M., Lee, Sandra , Krämer, Pauline , Leung, Samuel , Kang, Eun Young , Meagher, Nicola S. , Kennedy, Catherine J. , Boros, Jessica , Kommoss, Friedrich, Vollert, Hans‐Walter, Harter, Philipp , Kraemer, Bernhard , Staebler, Annette , Heublein, Sabine , Sinn, Hans‐Peter , Singh, Naveena , Laslavic, Angela , Olawaiye, Alex, Moysich, Kirsten B. , Sharma, Raghwa , Brand, Alison H. , Harnett, Paul R. , DeFazio, Anna , Fortner, Renée T. , Lener, Marcin , Tołoczko‐Grabarek, Aleksandra, Coulson, Penny , El‐Bahrawy, Mona , Jones, Michael E. , Schoemaker, Minouk J. , Gayther, Simon A. , Carney, Michael E. , Shvetsov, Yurii B. , Hernandez, Brenda Y. , Goodman, Marc T. , Mateoiu, Constantina , Linder, Anna , Kelemen, Linda E. , Widschwendter, Martin , Menon, Usha , Alsop, Jennifer , Shah, Mitul , Jimenez‐Liñan, Mercedes , Brenton, James D. , Cushing‐Haugen, Kara L. , Huntsman, David G. , Nelson, Gregg , Tinker, Anna V. , Goode, Ellen L. , Ramus, Susan J. , Kommoss, Stefan , Talhouk, Aline , Köbel, Martin , Anglesio, Michael S. , Campbell, Ian G , Gilks, C. Blake , Köbel, Martin , Anglesio, Michael S , Fazio, Anna de , Fortner, Renée T , Ramus, Susan J , Menon, Usha , Brenton, James D , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Jones, Michael E , Brand, Alison H , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Hernandez, Brenda Y , Schoemaker, Minouk J , Goodman, Marc T , Linder, Anna , Cairns, Evan S. , Chiu, Derek S , Heitz, Florian , Bois, Andreas du , Grube, Marcel , Kommoss, Felix , Elishaev, Esther , Modugno, Francesmary , Lubiński, Jan , Cybulski, Cezary , Gronwald, Helena , Gronwald, Jacek , Swerdlow, Anthony J. , Gorringe, Kylie L. , Campbell, Ian , Cook, Linda S. , Wilkens, Lynne R. , Sundfeldt, Karin , Gentry‐Maharaj, Aleksandra , Bolton, Kelly L. , Pharoah, Paul D.P. , Harris, Holly R. , Doherty, Jennifer A. , Ghatage, Prafull , Lee, Cheng‐Han , Nelson, Brad H.

Mayo Clinic

The Journal of Pathology | December 13, 2021 | Volume: 256 | Issue: 4 | Pages: 388-401

10.1002/path.5849 | PMID 34897700 Get It

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis‐associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas, through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks. Validated immunohistochemical surrogate assays for ARID1A mutations were applied to all samples. We investigated associations between ARID1A loss/mutation, clinical features, outcome, CD8 + tumour‐infiltrating lymphocytes (CD8 + TILs), and DNA mismatch repair deficiency (MMRd). ARID1A loss was observed in 42% of CCOCs and 25% of ENOCs. We found no associations between ARID1A loss and outcomes, stage, age, or CD8 + TIL status in CCOC. Similarly, we found no association with outcome or stage in endometrioid cases. In ENOC, ARID1A loss was more prevalent in younger patients ( p = 0.012) and was associated with MMRd ( p < 0.001) and the presence of CD8 + TILs ( p = 0.008). Consistent with MMRd being causative of ARID1A mutations, in a subset of ENOCs we also observed an association with ARID1A loss‐of‐function mutation as a result of small indels ( p = 0.035, versus single nucleotide variants). In ENOC, the association with ARID1A loss, CD8 + TILs, and age appears confounded by MMRd status. Although this observation does not explicitly rule out a role for ARID1A influence on CD8 + TIL infiltration in ENOC, given current knowledge regarding MMRd, it seems more likely that effects are dominated by the hypermutation phenotype. This large dataset with consistently applied biomarker assessment now provides a benchmark for the prevalence of ARID1A loss‐of‐function mutations in endometriosis‐associated ovarian cancers and brings clarity to the prognostic significance. © 2021 The Pathological Society of Great Britain and Ireland.
DNA Methylation Profiles of Ovarian Clear Cell Carcinoma
Cunningham, Julie M. , Winham, Stacey J. , Wang, Chen , Weiglt, Britta, Fu, Zhuxuan, Armasu, Sebastian M., McCauley, Bryan M., Brand, Alison H., Chiew, Yoke-Eng , Elishaev, Esther, Gourley, Charlie , Kennedy, Catherine J. , Laslavic, Angela, Lester, Jenny, Piskorz, Anna, Sekowska, Magdalena, Brenton, James D. , DeFazio, Anna , Drapkin, Ronny , Huntsman, David G., Köbel, Martin , Konner, Jason, Lawrenson, Kate , Papaemmanuil, Elli, Bolton, Kelly L., Goode, Ellen L., Brand, Alison H. , Fu, Zhuxuan , Churchman, Michael , Fazio, Anna de , Drapkin, Ronny , Elias, Kevin M , Karlan, Beth Y , Köbel, Martin , Lawrenson, Kate , Modugno, Francesmary , Winham, Stacey J , Brenton, James D , Wang, Chen , Kennedy, Catherine J , Fu, Zhuxuan , Brand, Alison H , Chiew, Yoke-Eng , Cunningham, Julie M , Weiglt, Britta, Fu, Zhuxuan, Armasu, Sebastian M., McCauley, Bryan M., Brand, Alison H., Elishaev, Esther, Gourley, Charlie , Laslavic, Angela, Lester, Jenny, Piskorz, Anna, Sekowska, Magdalena, Huntsman, David G., Konner, Jason, Papaemmanuil, Elli, Bolton, Kelly L., Goode, Ellen L.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 25, 2021 | Volume: 31 | Issue: 1 | Pages: 132-141

10.1158/1055-9965.epi-21-0677 | PMID 34697060 Get It

Abstract Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N = 137), Cluster 1 cases (N = 134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P &lt; 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P &lt; 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P &lt; 10−4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNγ responses (P &lt; 10−6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways. Impact: This work serves as a foundation for integrative analyses that better understand the complex biology of OCCC in an effort to improve potential for development of targeted therapeutics.
Circulating CD14+HLA‐DRlo/− monocytic cells as a biomarker for epithelial ovarian cancer progression
Stenzel, Ashley E. , Abrams, Scott I. , Joseph, Janine M. , Goode, Ellen L. , Tario, Joseph D. , Wallace, Paul K. , Kaur, Divjot , Adamson, Anna‐Kay, Buas, Matthew F. , Lugade, Amit A., Laslavic, Angela , Orr, Brian , Odunsi, Kunle , Etter, John Lewis , Moysich, Kirsten B. , Moysich, Kirsten , Buas, Matthew F , Kaur, Divjot, Taylor, Sarah E , Edwards, Todd , Elishaev, Esther , Mongiovi, Jennifer M. , Winham, Stacey J. , Kaufmann, Scott H. , Modugno, Francesmary

Mayo Clinic

American Journal of Reproductive Immunology | September 22, 2020 | Volume: 85 | Issue: 3 | Pages: No page available

10.1111/aji.13343 | PMID 32905653 Get It

AbstractProblemPrevious studies identified circulating CD14+HLA‐DRlo/− monocytic cells as an immune suppressive subset in solid malignancies, such as prostate, renal cell carcinoma, and pancreatic cancer. Such monocytic cells have been implicated not only in tumour progression but also as a potential barrier for immunotherapy. This study examined the relationship between the frequency of circulating monocytic cells and epithelial ovarian cancer (EOC) progression pre‐ and post‐frontline chemotherapy, defined by disease stage, which is a leading prognostic factor for this malignancy.Method of studyIncident cases of 236 women with EOC were recruited and comprehensive flow cytometry was utilized to assess the frequency of peripheral blood CD33+CD11b+HLA‐DR−/lowCD14+CD15− monocytic cells, henceforth termed CD14+HLA‐DRlo/− monocytic cells, prior to and after completion of frontline chemotherapy. Multivariable odds ratios (OR) were used to estimate the association between CD14+HLA‐DRlo/− monocytic cell percentages and disease stage. Wilcoxon signed‐rank tests evaluated changes in these monocytic cell levels pre‐ and post‐chemotherapy in a patient subset (n = 70).ResultsPatients with elevated frequencies of circulating CD14+HLA‐DRlo/− monocytic cells at diagnosis were at 3.33‐fold greater odds of having advanced stage (III/IV) EOC (CI: 1.04‐10.64), with a significant trend in increasing CD14+HLA‐DRlo/−monocytic cell levels (P = .04). There was a 2.02% median decrease of these monocytic cells post‐chemotherapy among a subset of patients with advanced stage disease (P < .0001).ConclusionThese findings support the potential clinical relevance of CD14+HLA‐DRlo/−monocytic cells in EOC for prognosis and may indicate a non‐invasive biomarker to measure disease progression.